Lipid Profiling Reveals Browning Heterogeneity of White Adipose Tissue by Β3-Adrenergic Stimulation.
browning heterogeneity
lipid profiling
subcutaneous adipose tissue
visceral adipose tissue
white adipose tissue
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
03 09 2019
03 09 2019
Historique:
received:
28
07
2019
revised:
27
08
2019
accepted:
29
08
2019
entrez:
6
9
2019
pubmed:
6
9
2019
medline:
28
7
2020
Statut:
epublish
Résumé
White adipose tissue (WAT) browning confers beneficial effects on metabolic diseases. However, visceral adipose tissue (VAT) is not as susceptible to browning as subcutaneous adipose tissue (SAT). Interpreting the heterogeneity of VAT and SAT in brown remodeling and provide promising lipid targets to promote WAT browning. We first investigated the effects of β3-adrenergic stimulation by CL316,243 on systemic metabolism. Then, high-coverage targeted lipidomics approach with multiple reaction monitoring (MRM) was utilized to provide extensive detection of lipid metabolites in VAT and SAT. CL316,243 notably ameliorated the systemic metabolism and induced brown remodeling of SAT but browning resistance of VAT. Comprehensive lipidomics analysis revealed browning heterogeneity of VAT and SAT with more dramatic alteration of lipid classes and species in VAT rather than SAT, though VAT is resistant to browning. Adrenergic stimulation differentially affected glycerides content in VAT and SAT and boosted the abundance of more glycerophospholipids species in VAT than in SAT. Besides, CL316,243 increased sphingolipids in VAT without changes in SAT, meanwhile, elevated cardiolipin species more prominently in VAT than in SAT. We demonstrated the browning heterogeneity of WAT and identified potential lipid biomarkers which may provide lipid targets for overcoming VAT browning resistance.
Sections du résumé
BACKGROUND
White adipose tissue (WAT) browning confers beneficial effects on metabolic diseases. However, visceral adipose tissue (VAT) is not as susceptible to browning as subcutaneous adipose tissue (SAT).
AIM
Interpreting the heterogeneity of VAT and SAT in brown remodeling and provide promising lipid targets to promote WAT browning.
METHODS
We first investigated the effects of β3-adrenergic stimulation by CL316,243 on systemic metabolism. Then, high-coverage targeted lipidomics approach with multiple reaction monitoring (MRM) was utilized to provide extensive detection of lipid metabolites in VAT and SAT.
RESULTS
CL316,243 notably ameliorated the systemic metabolism and induced brown remodeling of SAT but browning resistance of VAT. Comprehensive lipidomics analysis revealed browning heterogeneity of VAT and SAT with more dramatic alteration of lipid classes and species in VAT rather than SAT, though VAT is resistant to browning. Adrenergic stimulation differentially affected glycerides content in VAT and SAT and boosted the abundance of more glycerophospholipids species in VAT than in SAT. Besides, CL316,243 increased sphingolipids in VAT without changes in SAT, meanwhile, elevated cardiolipin species more prominently in VAT than in SAT.
CONCLUSIONS
We demonstrated the browning heterogeneity of WAT and identified potential lipid biomarkers which may provide lipid targets for overcoming VAT browning resistance.
Identifiants
pubmed: 31484405
pii: biom9090444
doi: 10.3390/biom9090444
pmc: PMC6770315
pii:
doi:
Substances chimiques
Adrenergic beta-3 Receptor Agonists
0
Dioxoles
0
Receptors, Adrenergic, beta-3
0
disodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate
138908-40-4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK020595
Pays : United States
Organisme : NIDDK NIH HHS
ID : R00 DK090210
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK109015
Pays : United States
Références
J Clin Invest. 2010 Aug;120(8):2876-88
pubmed: 20592469
Eur J Biochem. 1993 Mar 15;212(3):727-35
pubmed: 8385010
Endocr Rev. 2008 Jun;29(4):381-402
pubmed: 18451260
J Clin Invest. 1998 Jul 15;102(2):412-20
pubmed: 9664083
Cell Rep. 2014 Dec 11;9(5):1584-1593
pubmed: 25466254
Cell Rep. 2017 Feb 7;18(6):1558-1572
pubmed: 28178530
Clin Pharmacol Ther. 2014 Jan;95(1):53-66
pubmed: 24105257
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jan;1864(1):3-12
pubmed: 29704660
J Biol Chem. 2011 Jan 14;286(2):899-908
pubmed: 21068380
Cell Metab. 2008 May;7(5):410-20
pubmed: 18460332
Prog Lipid Res. 2013 Apr;52(2):206-19
pubmed: 23295259
Chem Phys Lipids. 1999 Apr;98(1-2):69-77
pubmed: 10358929
Nutr Diabetes. 2014 Oct 20;4:e141
pubmed: 25329603
Life Sci. 1997;61(19):1907-14
pubmed: 9364195
Cell Metab. 2014 Oct 7;20(4):687-95
pubmed: 25295789
Neurobiol Aging. 2014 Oct;35(10):2369-81
pubmed: 24684787
Prog Lipid Res. 2009 Sep;48(5):275-97
pubmed: 19464318
Diabetologia. 2000 May;43(5):533-49
pubmed: 10855527
PLoS One. 2010 Jul 12;5(7):e11525
pubmed: 20634946
J Clin Hypertens (Greenwich). 2019 Feb;21(2):239-242
pubmed: 30525276
Prog Lipid Res. 2014 Jul;55:1-16
pubmed: 24769127
J Clin Endocrinol Metab. 1992 Jul;75(1):15-20
pubmed: 1320047
Am J Clin Nutr. 2003 May;77(5):1192-7
pubmed: 12716671
Am J Physiol Endocrinol Metab. 2005 Oct;289(4):E608-16
pubmed: 15941787
Biochim Biophys Acta. 2015 May;1853(5):918-28
pubmed: 25655664
Int J Biochem Cell Biol. 2014 Nov;56:123-32
pubmed: 25240584
Prog Lipid Res. 2000 May;39(3):257-88
pubmed: 10799718
Life Sci. 2014 Nov 18;118(1):7-14
pubmed: 25445436
Prog Lipid Res. 2013 Oct;52(4):590-614
pubmed: 24007978
J Biol Chem. 2006 Dec 29;281(52):40236-41
pubmed: 17074755
Obes Rev. 2010 Jan;11(1):11-8
pubmed: 19656312
Biochim Biophys Acta. 2013 May;1831(5):924-33
pubmed: 23376222
J Genet Genomics. 2013 Aug 20;40(8):375-90
pubmed: 23969247
Diabetologia. 2016 Apr;59(4):785-98
pubmed: 26739815
Mol Biosyst. 2010 Jun;6(6):1008-17
pubmed: 20485745
Cell Metab. 2016 Jun 14;23(6):1200-1206
pubmed: 27238638
Trends Biochem Sci. 1998 Nov;23(11):423-8
pubmed: 9852760
Biochim Biophys Acta. 2014 May;1841(5):671-81
pubmed: 24021978
Cell. 2012 Oct 12;151(2):400-13
pubmed: 23063128
Cell Metab. 2016 Dec 13;24(6):820-834
pubmed: 27818258
Trends Cell Biol. 2018 Jan;28(1):67-76
pubmed: 28911913
Curr Diabetes Rev. 2006 Nov;2(4):367-73
pubmed: 18220642
Diabetes. 2014 Aug;63(8):2620-30
pubmed: 24677714
Biochim Biophys Acta. 1992 Mar 26;1113(1):71-133
pubmed: 1550861
Annu Rev Biochem. 2014;83:79-98
pubmed: 24606142
J Lipid Res. 2014 Dec;55(12):2541-53
pubmed: 25271296
Cell Metab. 2014 Oct 7;20(4):678-86
pubmed: 25295788
Nucl Med Biol. 2014 Jan;41(1):10-6
pubmed: 24090673
Front Physiol. 2013 Oct 03;4:265
pubmed: 24106479
J Clin Invest. 2011 Apr;121(4):1402-11
pubmed: 21403394
Cell Rep. 2018 Jul 17;24(3):781-790
pubmed: 30021173
Comp Biochem Physiol A Mol Integr Physiol. 1998 Feb;119(2):629-36
pubmed: 11249012
Cell. 2014 Jan 16;156(1-2):20-44
pubmed: 24439368